BR0207865A - Benzotiadiazinas inibidores de metaloproteinases de matriz - Google Patents
Benzotiadiazinas inibidores de metaloproteinases de matrizInfo
- Publication number
- BR0207865A BR0207865A BR0207865-1A BR0207865A BR0207865A BR 0207865 A BR0207865 A BR 0207865A BR 0207865 A BR0207865 A BR 0207865A BR 0207865 A BR0207865 A BR 0207865A
- Authority
- BR
- Brazil
- Prior art keywords
- benzothiadiazines
- matrix metalloproteinase
- metalloproteinase inhibitors
- alkyl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
"BENZOTIADIAZINAS INIBIDORAS DE METALO-PROTEINASES DE MATRIZ". Os inibidores de MMP-13 seletivos são benzo tiadiazinas de Fórmula ou um seu sal farmaceuticamente aceitável, em que R^ 2^ é hidrogênio ou alquila; R^ 1^ e R^ 3^ incluem hidrogênio, alquila, e arila, com a condição de que R^ 3^ não seja (CH~ 2~)m~ bifenila ou (CH~ 2~)m~ bifenila substituída; X é O ou NH, n é 0, 1, ou 2. Os compostos de Fórmula I, ou o seu sal farmaceuticamonte aceitável, é útil para o tratamento de doenças mediadas por uma enzima MMP-13, incluindo doenças selecionadas de osteoartrite, artrite reumatóide, câncer, inflamação, e insuficiência cardíaca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26878201P | 2001-02-14 | 2001-02-14 | |
PCT/IB2002/000083 WO2002064578A1 (en) | 2001-02-14 | 2002-01-11 | Benzo thiadiazine matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0207865A true BR0207865A (pt) | 2004-03-23 |
Family
ID=23024450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0207865-1A BR0207865A (pt) | 2001-02-14 | 2002-01-11 | Benzotiadiazinas inibidores de metaloproteinases de matriz |
Country Status (17)
Country | Link |
---|---|
US (1) | US6656932B2 (pt) |
EP (1) | EP1368327B1 (pt) |
JP (1) | JP2004518726A (pt) |
AT (1) | ATE280164T1 (pt) |
BR (1) | BR0207865A (pt) |
CA (1) | CA2433075A1 (pt) |
DE (1) | DE60201665T2 (pt) |
DO (1) | DOP2002000336A (pt) |
ES (1) | ES2231708T3 (pt) |
GT (1) | GT200200016A (pt) |
HN (1) | HN2002000227A (pt) |
MX (1) | MXPA03005870A (pt) |
PA (1) | PA8538501A1 (pt) |
PE (1) | PE20020953A1 (pt) |
TN (1) | TNSN02013A1 (pt) |
UY (1) | UY27155A1 (pt) |
WO (1) | WO2002064578A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
CA2462442A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
CA2492391A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
MXPA05000476A (es) * | 2002-07-17 | 2005-03-23 | Warner Lambert Co | Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
AU2003247024A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
BR0313727A (pt) * | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de isoquinolina como inibidores de metaloproteinase da matriz |
AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
WO2004014869A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
WO2004014377A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
CA2497658A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
AU2003249534A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
JP2006500351A (ja) | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテアーゼ−13阻害剤としてのピリミジン−2,4−ジオン誘導体 |
WO2004014909A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
BR0313459A (pt) * | 2002-08-13 | 2005-06-21 | Warner Lambert Co | Derivados monocìclicos como inibidores de metaloproteinases de matriz |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
US7570259B2 (en) | 2004-06-01 | 2009-08-04 | Intel Corporation | System to manage display power consumption |
ATE405553T1 (de) | 2004-12-08 | 2008-09-15 | Bristol Myers Squibb Co | Heterocyclische verbindungen als inhibitoren von faktor viia |
SI1860098T1 (sl) | 2005-03-16 | 2013-03-29 | Toyama Chemical Co., Ltd. | Nov derivat antranilne kisline ali sol le-tega |
LT2445502T (lt) * | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
CA2830511C (en) | 2011-03-18 | 2021-09-14 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
EP3718536A1 (en) | 2012-09-19 | 2020-10-07 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
MA39495A (fr) | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Ltd | Formulations d'aripiprazole présentant des vitesses d'injection plus élevées |
EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
CN113773277B (zh) * | 2021-09-18 | 2023-12-05 | 兰州大学 | 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242443B1 (en) * | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
AU741768B2 (en) * | 1996-12-09 | 2001-12-06 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
US6630464B1 (en) * | 1997-04-28 | 2003-10-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用 |
WO2001009485A1 (fr) | 1999-07-30 | 2001-02-08 | Yoshikane Ikitake | Moteur a combustion interne rotatif equipe de palettes a mouvements alternatifs |
PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
PL362919A1 (en) | 2000-10-26 | 2004-11-02 | Pfizer Products Inc. | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
KR20040004412A (ko) | 2000-10-26 | 2004-01-13 | 화이자 프로덕츠 인크. | 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
-
2002
- 2002-01-11 EP EP02740094A patent/EP1368327B1/en not_active Expired - Lifetime
- 2002-01-11 WO PCT/IB2002/000083 patent/WO2002064578A1/en active IP Right Grant
- 2002-01-11 BR BR0207865-1A patent/BR0207865A/pt not_active IP Right Cessation
- 2002-01-11 MX MXPA03005870A patent/MXPA03005870A/es unknown
- 2002-01-11 AT AT02740094T patent/ATE280164T1/de not_active IP Right Cessation
- 2002-01-11 ES ES02740094T patent/ES2231708T3/es not_active Expired - Lifetime
- 2002-01-11 CA CA002433075A patent/CA2433075A1/en not_active Abandoned
- 2002-01-11 JP JP2002564511A patent/JP2004518726A/ja not_active Abandoned
- 2002-01-11 DE DE60201665T patent/DE60201665T2/de not_active Expired - Fee Related
- 2002-02-01 DO DO2002000336A patent/DOP2002000336A/es unknown
- 2002-02-05 PA PA20028538501A patent/PA8538501A1/es unknown
- 2002-02-07 GT GT200200016A patent/GT200200016A/es unknown
- 2002-02-08 UY UY27155A patent/UY27155A1/es not_active Application Discontinuation
- 2002-02-11 HN HN2002000227A patent/HN2002000227A/es unknown
- 2002-02-12 PE PE2002000109A patent/PE20020953A1/es not_active Application Discontinuation
- 2002-02-13 TN TNTNSN02013A patent/TNSN02013A1/fr unknown
- 2002-02-13 US US10/074,646 patent/US6656932B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20020156069A1 (en) | 2002-10-24 |
DE60201665T2 (de) | 2006-02-02 |
EP1368327A1 (en) | 2003-12-10 |
UY27155A1 (es) | 2002-09-30 |
EP1368327B1 (en) | 2004-10-20 |
TNSN02013A1 (fr) | 2005-12-23 |
HN2002000227A (es) | 2002-10-23 |
PE20020953A1 (es) | 2002-10-25 |
US6656932B2 (en) | 2003-12-02 |
ATE280164T1 (de) | 2004-11-15 |
MXPA03005870A (es) | 2005-02-14 |
DOP2002000336A (es) | 2003-01-31 |
DE60201665D1 (de) | 2004-11-25 |
GT200200016A (es) | 2002-10-01 |
PA8538501A1 (es) | 2002-09-17 |
ES2231708T3 (es) | 2005-05-16 |
JP2004518726A (ja) | 2004-06-24 |
WO2002064578A1 (en) | 2002-08-22 |
CA2433075A1 (en) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0207865A (pt) | Benzotiadiazinas inibidores de metaloproteinases de matriz | |
EA200200976A1 (ru) | Способ лечения или ингибирования полипов ободочной кишки | |
EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
EA200100411A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
NO953305D0 (no) | Antranilsyrederivat | |
ATE377004T1 (de) | Proteinkinaseinhibitoren | |
ATE457025T1 (de) | Kinaseinhibitoren | |
ATE309237T1 (de) | Aromatische heterozyklische verbindungen als antientzündungwirkstoffe | |
DE69809187D1 (de) | Metalloproteinase-Inhibitoren | |
ATE349435T1 (de) | Dpiv-inhibitoren auf glutaminbasis | |
EA199800579A1 (ru) | Новые производные 5-амино-3-циано-4-этилсульфинил-1-фенилпиразола и их применение в качестве пестицидов | |
MEP61208A (en) | Novel compounds having inhibitory activity against sodium-dependant transporter | |
DK1485359T3 (da) | Natriumkanalblokkere | |
BR0010598A (pt) | Azoles substituìdos | |
DE60023318D1 (de) | Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren | |
ATE172717T1 (de) | Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen | |
IS6309A (is) | Kínasólínafleiður | |
DE60002714D1 (de) | Substituierte azaoxindolederivate | |
DK0952148T3 (da) | Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater | |
DK1109817T3 (da) | Phosphohalogenhydriner, deres fremstilling og anvendelse | |
DE69723258D1 (de) | Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren | |
EA200300392A1 (ru) | Производные пиперазина с мостиковой связью | |
BRPI0416678A (pt) | pirazolpirimidinas | |
EA200100040A1 (ru) | Химический синтез морфолиновых производных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |